Biotechnology Investments
After information technology, biotechnology and life sciences are the next wave of knowledge-based economy, creating numerous new opportunities for health as well as economies. Biotechnology sector must be addressed with great care and sensitivity, with relevant responsibilities across a broad range of activities. BioSciences understands all the present-day challenges and works with drug candidates from the very beginning up to their established marketing. It provides effective coordination and addresses the challenges and opportunities of these new technologies. Public research laboratories and academic institutions, which interacts with enterprise-based research and private bodies investments. The success of any biotechnology rests upon the generation, distribution and application of new knowledge and technologies.
BioScienses Infrastructure
With all its extensive and efficient infrastructure and experience in in-licensing, investments, clinical and corporate developments, BioSciences helps prospective drug candidates easily navigate through regulatory pathways and build up a strong presentation on the competitive market. Chelsea Therapeutics, originated and managed by Dr. Lindsay Rosenwald, has been built around a novel anti-folate developed to treat inflammatory conditions, including psoriasis and rheumatoid arthritis (RA). The compound, originally called CH-1504 and developed at Chelsea Therapeutics, has shown benefits in terms of both efficacy and safety over the current treatment standard for RA – Methotrexate, which elevated liver enzymes in numerous patients.
A rather interesting academic drug candidate was in-licensed by MD Anderson Cancer Center, – organic arsenic trioxide compound. This compound was approved by FDA and progressed from IND to NDA within just 30 months, which is considered to be the quickest FDA regulatory approval. An inorganic alternative of arsenic trioxide called Trisenox, if taken at high doses, was found to produce cardiac abnormalities. Comparing with the inorganic compound, organic arsenic trioxide is free from these problems even when used at doses 10-20 times higher than Trisenox. To investigate and promote this advantage, Dr. Rosenwald has founded a new portfolio company called Ziopharm Oncology, with its main goal to advance ZIO-101, the new organic arsenic compound, research and promote the drug to help in treating cancers, including solid tumors, where larger doses has proven to be effective. Ziopharm Oncology has afterwards in-licensed and developed several other agents to treat cancers and is currently working on new anti-cancer agents.
Keryx Biopharmaceuticals has almost completed its development of Sulonex, a compound aimed at the treatment of diabetic nephropathy. Sulonex was in-licensed from the Alfa Wassermann Group, a private pharmaceutical company in Italy.
With a revolution taking place in the knowledgebase of biotechnology and life sciences, it becomes vitally important to give way to new research and applications in the sphere of healthcare and supplements production, as well as new scientific discoveries. Dr. Rosenwald has contributed to the expansion of the knowledge base in the biotech sector and helped to transform frontier scientific inventions into practical use and drug products, which have a very good potential for new wealth creation. Biotechnology and life sciences, which are probably the most promising among the frontier technologies, can provide a major contribution to become a leading sphere in the present-day world.
As the industry leading company involved in building and supporting development infrastructure and financing operations in biotechnology and life sciences sectors,it represents a great market value. When it comes to improvement and enhancement of portfolio companies’ success. Due to its ability to work with drug candidates right from the beginning and up to their successful marketing. With its originator and chief executive officer Dr. Lindsay A. Rosenwald, has gained leading positions in the biotechnology and life sciences sector.